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Disease caused by Shiga toxin-producing
Escherichia coli (STEC) ranges from self-limiting
diarrhea to hemorrhagic colitis and hemolytic
uremic syndrome (HUS). Serotype O157:H7, the
most frequently implicated STEC causing hemor-
rhagic colitis and HUS, has been isolated from
large foodborne outbreaks, as well as sporadic
cases, in North America and abroad. However, 60
STEC serotypes have been implicated in diarrheal
disease, and several non-O157:H7 serotypes
have been implicated as the cause of foodborne
outbreaks and HUS in the United States, Europe,
and Australia. Studies from Canada, Europe,
Argentina, and Australia suggest that non-
O157:H7 STEC infections are as prevalent, or
more so, than O157:H7 infections.
E. coli O157:H7 is easily differentiated from
other E. coli by its inability to rapidly ferment
sorbitol; however, non-O157:H7 STEC are pheno-
typically similar to commensal nonpathogenic
E. coli and are not detected with sorbitol
MacConkey agar. To detect non-O157:H7 STEC,
nonculture methods are used (enzyme immu-
noassay [EIA] or polymerase chain reaction
[PCR]), which are typically only performed in
reference laboratories. The purpose of this study
was to determine the prevalence of non-O157:H7
STEC in persons with diarrhea in  Nebraska.
The Study
Nine regional clinical microbiology laborato-
ries in Nebraska sent stool samples from March
1, 1998, to October 31, 1998, to the Nebraska
Public Health Laboratory, University of Ne-
braska Medical Center. All stool samples that
were sent to a participating laboratory with a
physician’s order to screen for enteric pathogens
were included. Thus, all samples were from
patients with a differential diagnosis of bacterial
gastroenteritis. Patients who had been in the
hospital for >2 days before diarrhea developed
were excluded. The samples were added to a
Para-Pak C&S stool transport container (Merid-
ian Diagnostics, Cincinnati, OH) and sent by
courier to the Nebraska Public Health Laboratory.
Samples were plated to cefixime-tellurite
sorbitol MacConkey (CT-SMAC) agar plates and
screened for typical sorbitol-negative colonies (1).
Presumptive colonies were identified as E. coli by
API strips (Biomerieux Vitek, Hazelwood, MO)
and serotyped with RIM E. coli O157:H7 (Remel,
Lenexa, KS). Samples were injected into 10 mL
MacConkey broth (Difco, Detroit, MI) and
incubated overnight at 37°C. The Premier
enterohemorrhagic  E. coli (EHEC) assay was
performed by using 50 µL of overnight growth.
The reaction mixtures were read spectrophoto-
metrically at 450 nm and scored as positive or
negative. PCR was performed by first extracting
DNA from the overnight culture of MacConkey
broth using a QIAamp Tissue kit (Qiagen, Santa
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We determined the prevalence of Shiga toxin-producing Escherichia coli (STEC) in
diarrheal stool samples from Nebraska by three methods: cefixime-tellurite sorbitol
MacConkey (CT-SMAC) culture, enterohemorrhagic E. coli (EHEC) enzyme
immunoassay, and stx1,2 polymerase chain reaction (PCR). Fourteen (4.2%) of 335
specimens were positive by at least one method (CT-SMAC culture [6 of 14], EHEC
enzyme immunoassay [13 of 14], stx1,2 PCR [14 of 14]).  Six contained serogroup 0157,
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Table 1. Results of CT-SMAC culture, enzyme
immunoassay, and stx polymerase chain reaction
   CT-
Laboratory Isolate Serotype SMACa EIA PCR
A A1 O157:H7 + + +
A2 O157:H7 + + +
A3 O26:H11  - + +
A4 O157:NM + + +
B B1 O145:NM  - + +
B2 O103:H2  - + +
B3 O157:NM +  - +
CN I b NI  - + +
D D1 O111:NM  - + +
D2 O111:NM  - + +
D3 O157:H7 + + +
D4 O157:H7 + + +
E E1 Orough:H2  - + +
E2 O26:H11  - + +
a(+) Denotes a positive CT-SMAC culture, EIA, or stx PCR; (-)
denotes a negative CT-SMAC culture, EIA, or stx PCR; CT-
SMAC = cefixime-tellurite sorbitol MacConkey agar; EIA =
enzyme immunoassay; PCR = polymerase chain reaction.
bNI = Not isolated.
Table 2. Results from multiplex polymerase chain
reaction (PCR) amplification
Isolate Serotype stx1a stx2 eae ehxA
A1 O157:H7 + + + +
A2 O157:H7  - + + +
A3 O26:H11 +  - + +
A4 O157:NM + + + +
B1 O145:NM +  - + +
B2 O103:H2 +  - + +
D1 O111:NM + + + +
D2 O111:NM + + + +
D3 O157:H7  - + + +
D4 O157:H7 + + + +
E1 Orough:H2 +  - + +
E2 O26:H11 +  - + +
a(+) Denotes presence of gene as assessed by PCR; (-) denotes
absence of gene as assessed by PCR.
Clarita, CA). The following set of primers, which
detects both stx1 and stx2, was used: 5'TTTACG
ATAGACTTCTCGAC3' and 5'CACATATAA TTA
TTTCGCTC3' (2). E. coli O157:H7 strain G5244
was used as positive control (Centers for Disease
Control and Prevention [CDC] strain collection).
Samples Shiga-toxin positive by either EHEC
enzyme EIA, PCR, or both were plated onto
sheep-blood agar (Remel) and streaked for
isolation. After overnight growth, multiple E. coli-
like colonies were selected for retesting by using
the Premier EHEC assay. Positive colonies were
identified to species level by using API strips and
serotyped by CDC.
Multiplex PCR (3) was performed on isolated
Shiga toxin-positive colonies to detect specific
genes encoding Shiga toxins 1 and 2 (stx1 and
stx2), intimin (eaeA), and enterohemolysin A
(ehxA). Genomic DNA suitable for pulsed-field
gel electrophoresis (PFGE) was prepared (4) and
digested with XbaI (Roche, Indianapolis, IN).
E. coli O157:H7 G5244 was used as a standard.
PFGE patterns were captured by a Bio-Rad Gel-
Doc system and were analyzed by Molecular
Analyst software (Bio-Rad, Hercules, CA).
Of the nine clinical laboratories that
submitted 335 samples during the study period,
five submitted samples positive by CT-SMAC
culture, EIA, or stx  PCR  (Table 1). Fourteen
4.2%) samples were positive by at least one of the
methods; 13 of these were obtained either
through direct culture by using CT-SMAC or
through Shiga toxin screening and subsequent
colony isolation. Six of the thirteen were serotype
O157:H7 or O157:NM; seven were non-O157
serotypes. All seven of the non-O157 isolates
were the predominant species found in the
culture when the sample was plated on sheep-
blood agar. All six E. coli O157:H7 or O157:NM
isolates were detected by using CT-SMAC
culture and stx PCR; five of six were detected by
EIA. All of seven non-O157 isolates were detected
by EIA or stx PCR. One sample (isolate B3) that
was negative by EIA but positive by PCR and CT-
SMAC culture was subsequently found to be
positive by EIA when tested individually. One
sample from laboratory C was positive for EIA
and stx PCR (both tests were weak positives), but
no Shiga toxin-positive colony was obtained upon
repeat subculture. The low prevalence of this
organism in the stool sample may reflect STEC
carriage in this patient. By the combined results
of both culture and EIA as the reference standard
(14 samples positive, 321 samples negative),
the sensitivity and specificity of the stx PCR (14
samples positive, 321 samples negative) were
each 100%.
PCR was performed on the 13 isolated STEC
to detect stx1, stx2, eae, and ehxA (Table 2). All
isolates, regardless of serotype, encoded eae and
ehxA; three of five O157 isolates encoded both stx1
and  stx2; two of seven non-O157:H7 isolates
encoded stx2 (both O111:NM). PFGE showed that
all but two STEC isolates were unrelated; isolates
D1 and D2 (both O111:NM), which were isolated
from samples sent from the same laboratory, were
indistinguishable (data not shown).532 Emerging Infectious Diseases Vol. 6, No. 5, September–October 2000
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Conclusions
In a 1997 study of 30,000 diarrheal stool
samples, E. coli O157:H7 was the fourth most
prevalent bacterial enteric pathogen (5). How-
ever, the incidence of non-O157 STEC in the
United States is not well established. Studies
from Europe have shown that the prevalence of
STEC in diarrheal samples is 0.3% to 9.3%;
serogroup O157 prevalence is 0% to 2.7%. In
Australia, serotype O111:NM is the most
frequent cause of serious human disease and has
been associated with outbreaks. In a recent study
of 3,289 diarrheal samples from clinical
laboratories in the United States, non-O157
STEC were more prevalent than O157 serotypes
(6). STEC was found to be as prevalent (1.2%) as
Shigella sp. (1.4%), and almost as prevalent as
Salmonella  sp. (2.4%) and Campylobacter  sp.
(2.0%). Testing for E. coli O157:H7 alone would
have missed up to 50% of STEC.
Our study is the first to address the
prevalence of non-O157 STEC in diarrheal
samples from the Great Plains region of the
northern United States, where cattle and other
animal reservoirs of STEC are abundant. In our
study, 4.2% of the samples were positive for
STEC by CT-SMAC culture, PCR, or Meridian
EHEC EIA. Though this prevalence is higher
than previously reported in the United States,
other studies have shown that northern states
have a higher prevalence of E. coli O157:H7 (7).
In addition, Nebraska has a large rural
population, whose members may have contact
with animal reservoirs that carry STEC. Five
different non-O157 STEC serotypes were iso-
lated: O111:NM, O26:H11, O145:NM, O103:H2,
and Orough:H2. Four of these are associated with
HUS (O111:NM [8–10], O26:H11[11], O145:NM
[12], and O103:H2 [13]). In addition, serotypes
O111:NM and O26:H11 have been associated
with diarrhea in weaned calves (14). Although
most STEC cases are linked to eating undercooked
hamburger (15), contact with food animals has
also been implicated as a source of infection (16).
Shiga toxins 1 and 2 are the main virulence
factors associated with hemorrhagic colitis and
HUS, presumably because they interact with
endothelial cells at the site of infection and in the
glomeruli and arterioles of the kidney (17). stx1
and stx2 are highly related yet immunologically
distinct. STEC produce other accessory viru-
lence  factors, including intimin (eae) and
enterohemolysin A (ehxA). The former is
responsible for the characteristic histopathologic
feature known as the attaching and effacing (A/E)
lesion (18); ehxA is a hemolysin encoded by the
90-kb virulence-associated plasmid found in most
STEC infecting humans (19). A study of 237
isolates from 118 serotypes found a significant
association between stx2 and eae in isolates that
caused hemorrhagic colitis and HUS in humans
(20) and between ehxA and severe disease. STEC
isolates from asymptomatic human carriers
usually do not encode eae and therefore may not
have a mechanism to adhere to intestinal
epithelial cells (21). However, STEC isolates
lacking the eae gene have been associated with
hemorrhagic colitis and HUS (22). All STEC
isolates obtained in this study encoded both eae
and ehxA. The six O157 isolates also encoded stx2,
as did both O111:NM isolates, which indicates
that at least these eight isolates could produce
serious disease. Five of seven non-O157 isolates
encoded  stx1  only; however, STEC isolates
associated with hemorrhagic colitis and HUS
that encoded only  stx1 have been reported (23).
All O157:H7, O157:NM, and O26:H11 isolates
in our study were distinct by PFGE RFLP
patterns, which suggests that these cases were
sporadic. However, two O111:NM isolates (D1
and D2) from the same community had
indistinguishable PFGE RFLP patterns. The
isolates were from different patients and were
cultured within 1 day of each other. This suggests
that an outbreak of O111:NM may have occurred
that was not detected by standard laboratory
techniques. However, without epidemiologic
information, these results are difficult to interpret.
This study demonstrated that non-O157
STEC serotypes are at least as prevalent as
serogroup O157 in diarrheal samples from
Nebraska. Non-O157 STEC isolates presumably
were the cause of diarrhea in 7 of 14 positive
samples. These non-O157 isolates carried known
STEC virulence genes and were the predominant
organism found in culture. Other bacterial
pathogens such as Salmonella, Shigella, and
Campylobacter  were not isolated from these
seven samples. Our results suggest that stx PCR
is as sensitive and specific as CT-SMAC culture
and EIA combined, and therefore may be used as
an alternate method to diagnose diarrheal
infections caused by STEC. Clinical laboratories
may need to implement serotype-independent
methods to avoid underdiagnosis of STEC-
mediated bacterial gastroenteritis.Vol. 6, No. 5, September–October 2000 Emerging Infectious Diseases 533
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